Mediwound Ltd
NASDAQ:MDWD
Intrinsic Value
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard... [ Read More ]
The intrinsic value of one MDWD stock under the Base Case scenario is 10.249 USD. Compared to the current market price of 17.643 USD, Mediwound Ltd is Overvalued by 42%.
Valuation Backtest
Mediwound Ltd
Run backtest to discover the historical profit from buying and selling MDWD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Mediwound Ltd
Current Assets | 49.7m |
Cash & Short-Term Investments | 71.6m |
Receivables | 5.1m |
Other Current Assets | -27m |
Non-Current Assets | 16.8m |
PP&E | 15.9m |
Intangibles | 165k |
Other Non-Current Assets | 673k |
Current Liabilities | 10.8m |
Accounts Payable | 5.5m |
Other Current Liabilities | 5.3m |
Non-Current Liabilities | 24m |
Long-Term Debt | 6.4m |
Other Non-Current Liabilities | 17.7m |
Earnings Waterfall
Mediwound Ltd
Revenue
|
18.7m
USD
|
Cost of Revenue
|
-15.1m
USD
|
Gross Profit
|
3.6m
USD
|
Operating Expenses
|
-19.1m
USD
|
Operating Income
|
-15.5m
USD
|
Other Expenses
|
8.8m
USD
|
Net Income
|
-6.7m
USD
|
Free Cash Flow Analysis
Mediwound Ltd
MDWD Profitability Score
Profitability Due Diligence
Mediwound Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
Mediwound Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
MDWD Solvency Score
Solvency Due Diligence
Mediwound Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Mediwound Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MDWD Price Targets Summary
Mediwound Ltd
According to Wall Street analysts, the average 1-year price target for MDWD is 29.07 USD with a low forecast of 25.25 USD and a high forecast of 37.8 USD.
Shareholder Return
MDWD Price
Mediwound Ltd
Average Annual Return | -16.83% |
Standard Deviation of Annual Returns | 25.97% |
Max Drawdown | -83% |
Market Capitalization | 162.7m USD |
Shares Outstanding | 9 491 720 |
Percentage of Shares Shorted | 2.16% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
Contact
IPO
Employees
Officers
The intrinsic value of one MDWD stock under the Base Case scenario is 10.249 USD.
Compared to the current market price of 17.643 USD, Mediwound Ltd is Overvalued by 42%.